GoeGoe Honglin Pharm.
GoeGoe Honglin’s main products include: antihypertensive drug JUPOPINE® (Nifedipine Controlled-Release Tablets), antidiabetic drug RoToFier® (Glipizide Extended Release Tablets), antihypertensive drug JUPOSHU® (Amlodipine Besylate Tablets), and analgesic drug JUPOPHON® (Ibuprofen Sustained-Release Capsules). All the four aforementioned products have passed the Consistency Evaluation of Generic Drugs in Quality and Efficacy, among which JUPOPINE® and RoToFier® were among the first in China to obtain this certification.
All the above products have been included in national and alliance-based centralized drug procurement and are supplied in sufficient quantities. JUPOPINE® was selected in the 7th round of national centralized drug procurement. RoToFier®, JUPOPHON®, and JUPOSHU® participated in the successor projects of national centralized drug procurement: RoToFier® won the bid for the national market, while JUPOPHON® and JUPOSHU® were selected in 26 provinces and municipalities (all the above-mentioned selected regions include Jiangsu Province).
Product Recognition 
The antidiabetic drug RoToFier® (Glipizide Extended Release Tablets) was among the first in China to pass the Generic Drug Consistency Evaluation.
The antihypertensive drug JUPOPINE® (Nifedipine Controlled-Release Tablets) was among the first in China to pass the Generic Drug Consistency Evaluation, and was officially designated as "Nifedipine Controlled-Release Tablets."
The antihypertensive drug JUPOSHU® (Amlodipine Besylate Tablets) officially passed the Generic Drug Consistency Evaluation.
The analgesic drug JUPOPHON® (Ibuprofen Sustained-Release Capsules) officially passed the Generic Drug Consistency Evaluation.
Successful National Centralized Procurement Selections 
Selected for the Renewal Procurement of Drugs from National Centralized Procurement Batches 1-8
Ranked No. 1 in New Reported Procurement Volume
Centralized Execution Starts April 2026
Covered Region: Nationwide (China)
Re-selected in Guangdong Province's Volume-Based Procurement Project for Tinidazole and Other Drugs
Covered Region: Guangdong
Won selection in the Shanghai 15-Province Volume-Based Procurement Alliance
Primary Supply Regions: Shanghai, Beijing, Shandong, Jiangxi, Sichuan
Alternate Supply Regions: Yunnan, Zhejiang, Anhui, Chongqing, Gansu, Tianjin, Tibet
Re-selected in the Interprovincial Alliance Continuation Procurement for Expired National Centralized Procurement Products
Covered Region: Jiangsu, Shaanxi, Guangxi
Included in Fujian Province's Volume-Based Continuation Procurement Project for Batches 1–5
Covered Region: Fujian
Successfully re-selected in the 16-Province Alliance (Henan-led) Continuation Procurement Project for the 3rd and 5th Batch Drugs
Covered Region: Henan, Hebei, Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Hubei, Hunan, Hainan, Qinghai, Ningxia, Xinjiang, Guizhou
Selected in the 5th Round of National Centralized Drug Procurement
Selected for the Renewal Procurement of Drugs from National Centralized Procurement Batches 1-8
Ranked No. 1 in Reported Procurement Volume Among Manufacturers Passing Generic Consistency Evaluation (GCE)
Centralized Execution Starts April 2026
Covered Region: Nationwide (China)
Selected in the 7th Round of National Centralized Drug Procurement
Selected for the Renewal Procurement of Drugs from National Centralized Procurement Batches 1-8
Ranked No. 5 in New Reported Procurement Volume
Centralized Execution Starts April 2026
Covered Region: Nationwide (China)
Re-selected in the Guangdong Alliance Volume-Based Procurement for Amoxicillin and Other Drugs
Covered Region: Guangdong, Hunan, Guizhou, Gansu, Ningxia, Shanxi, Guangxi, Xinjiang, Hainan, Qinghai
Re-selected in the Interprovincial Alliance Continuation Procurement for Expired National Centralized Procurement Products
Covered Region: Jiangsu
Re-selected in the Continuation Procurement for the 2022 1st, 2nd, and 4th Batch National Centralized Procurement Drugs; directly renewed in 2023
Covered Region: Beijing
Re-selected in Henan Province's Volume-Based Linked Procurement for Clopidogrel Oral Formulations and other drugs
Covered Region: Henan
Selected in the Chongqing Alliance Continuation Procurement for the 1st and 3rd Round of National Volume-Based Drug Procurement.
Covered Region: Chongqing, Sichuan, Inner Mongolia, Hubei, Tibet, Shaanxi, Yunnan
Selected for the Renewal Procurement of Drugs from National Centralized Procurement Batches 1-8
Ranked No. 4 in New Reported Procurement Volume
Centralized Execution Starts April 2026
Covered Region: Nationwide (China)
Re-selected in the Guangdong Alliance Volume-Based Procurement for Apixaban and other drugs
Covered Region: Guangdong, Jiangxi, Yunnan, Anhui, Sichuan, Chongqing, Gansu, Fujian, Hubei, Hunan, Tibet
Re-selected in the Henan 13-Province Alliance Volume-Based Procurement
Covered Region: Henan, Guizhou, Jilin, Guangxi, Qinghai, Xinjiang, Hainan, Ningxia, Shanxi, Inner Mongolia, Heilongjiang, Liaoning
Re-selected in Shandong Province's Volume-Based Procurement for drugs with expired agreements
Covered Region: Shandong
Re-selected in the Jiangsu-Shaanxi Alliance Continuation Procurement Project for expired National Centralized Procurement drugs
Covered Region: Jiangsu, Shaanxi
© 2025 GoeGoe Honglin Biopharmaceutical (Jiangsu) Co., Ltd. All Rights Reserved. 
苏公网安备32110102321813号 苏ICP备2025220962号-1 苏网药械信备字〔2026〕000201号
GoeGoe Honglin(Jiangsu)
Beijing Honglin
GoeGoe Honglin Pharm.